https://www.businesswire.com/news/home/20180604006518/en/ > BOSTON--(BUSINESS WIRE)--Jun 4, 2018--Celltrion (KRX:068270) made an announcement that it will launch Bio CDMO (Contract Development and Manufacturing) business, in a bid to pursue open innovation for development of new drugs, at the 2018 BIO International Convention, the world’s premier life sciences event being held in Boston, June 4-7. > ‘Bio CDMO’ refers to i) outsourcing of biologic cell line development and production process, etc., and ii) manufacture outsourcing of non-clinical material, clinical material, and commercialized material.